Hispidol

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Hispidol ((Z)-Hispidol) 是炎症性肠病的潜在治疗剂；抑制 TNF-α 诱导的单核细胞与结肠上皮细胞的粘附，IC50 为 0.50 μM。

Hispidol ((Z)-Hispidol) is a potential therapeutic for inflammatory bowel disease; inhibits TNF-α induced adhesion of monocytes to colon epithelial cells with an IC50 of 0.50 μM.

Hispidol shows potent inhibitory effect (>70%) on the TNF-α-induced adhesion of monocytes to colon epithelial cells, which is one of the hallmark events leading to inflammatory bowel disease (IBD). Hispidol shows strong inhibitory activities against TNF-α-induced monocytic-colonic epithelial cell adhesion as well as LPS-induced TNF-α expression, is as an excellent candidate for IBD drug development. This inhibition of TNF-α expression by hispidol corresponds to the additional inhibitory activity against AP-1 transcriptional activity, which is another transcription factor required for high level TNF-α expression.

The oral administration of hispidol suppresses significantly and dose-dependently TNBS-induced rat colitis. Oral administration of hispidol suppresses TNBS-induced colitis in a dose-dependent manner. There is a significant recovery in body weight decrease and colon tissue edematous inflammation. A higher dose (30 mg/kg) of hispidol shows a similar recovery effect to that of 300 mg/kg sulfasalazine. In the colon tissues, TNBS induces a dramatic increase in the level of MPO, a biochemical marker of inflammation, which is suppressed significantly by hispidol in a dose-dependent manner.

(Z)-Hispidol

JAK/STAT Signaling

STAT

TNF-α

——

——

5786-54-9

254.24

C15H10O4

>98% (HPLC)

DMSO : ≥ 100 mg/mL; 393.33 mM

c1cc(ccc1/C=C\1/C(=O)c2c(O1)cc(cc2)O)O

——

(-20℃)

With Ice Pack

≥ 2 years